Embecta opens new global headquarters in Parsippany

Matthew Fazelpoor//January 26, 2023

At a ribbon-cutting ceremony Jan. 25 in Parsippany, Embecta Corp. officially opened its new global headquarters.

The move follows the April 2022 spinoff of Embecta, one of the largest pure-play diabetes care companies in the world, from Franklin Lakes-based Becton, Dickinson and Co. (BD).

The new office – located at 300 Kimball Drive, Suite 300 – will house roughly 180 employees, including members of the leadership team, global support functions and the North America commercial organization. The company has an estimated 2,000 worldwide employees.

Devdatt (Dev) Kurdikar, president and chief executive officer, Embecta — Kurdikar

“With a number of our employees making their homes in New Jersey, the ability to tap into one of the nation’s most significant concentrations of highly-educated, experienced medical technology talent, and easy access to international airports and interstate highways, we see Parsippany as the ideal location to establish our worldwide headquarters,” said Devdatt (Dev) Kurdikar, president and chief executive officer, Embecta. “We are a new company, but our roots in New Jersey go back nearly 100 years when, as part of BD, we developed the first dedicated insulin syringe in 1924. We’re looking forward to advancing that legacy as we continue to develop and provide solutions that make life better for people living with diabetes.”

Embecta says the 55,600-square-foot office suite is designed to give employees the tools and flexibility needed to collaborate both in-person and virtually as they work with geographically dispersed teams to meet the needs of customers in more than 100 different countries.

CBRE served as Embecta’s partner in choosing, designing and building out the office, which features open workspace with the latest videoconferencing technology, huddle rooms and reservable private spaces, as well as a showroom for product demonstrations and on-site customer meetings.

In a statement, Gov. Phil Murphy said he is pleased Embecta has chosen to make a long-term commitment to the Garden State, adding to the roster of life sciences and medical technology companies that are at the core of the state’s burgeoning innovation economy, which NJBIZ has extensively reported on.

“Diabetes is one of the world’s most pressing health care issues, with an enormous cost burden and a societal impact that extends to friends, loved ones and caregivers,” said Murphy. “Embecta’s vision of a life unlimited by diabetes is closely aligned with our own efforts to invest in, and expand, the state’s public health infrastructure.”